European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Home
/
update
/
details

Bruker Corporation Invests in NovAliX to Accelerate Drug Discovery Innovations

NextEdge Admin

10 Aug 2024

2 min 34 sec

Bruker Corporation has made a strategic minority investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in drug discovery services, headquartered in Strasbourg, France. This investment aims to accelerate NovAliX's growth and expand its presence in Europe and the United States.

The collaboration between Bruker and NovAliX will focus on advancing drug discovery technologies, particularly in functional structural biology and biophysical methods for studying molecular dynamics, drug interactions, and therapeutic mechanisms of action. Leveraging Bruker’s advanced biophysical tools, such as NMR, mass spectrometry, and single-cell biology techniques, NovAliX will enhance its drug discovery services, from target assessment to lead optimization.

Joint innovation efforts will include NMR studies on protein and RNA structures, X-ray crystallography for structure-guided drug discovery, and high-throughput SPR for kinetics and binding studies. The partnership will also explore novel therapeutic peptides and oligonucleotides, as well as unique research on intrinsically disordered proteins for condensate biology.

Looking ahead, Bruker and NovAliX plan to establish the Biophysics Institute for Biomedical Research (IBRB) in Strasbourg by 2026. This institute will foster collaboration between biotechs, start-ups, and academic groups, driving innovation in biophysics and drug discovery.

Stephan Jenn, President of NovAliX, emphasized that the partnership will strengthen their leadership in biophysics and drug discovery, while Dr. Falko Busse, President of Bruker BioSpin Group, highlighted the potential to support the discovery of new medicines through advanced biophysical tools.

Financial details of the investment were not disclosed. NovAliX has over 430 employees across its European R&D and CRO service sites, and is expanding its reach in the U.S. and Japan.